Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Lonza expands Visp bioconjugation plans and updates scale to 3,000 liters

Company / institutional announcement · Lonza

Source published: · Event / reporting date: 2026-10-29

Site published: 2026-11-05 · Updated: 2026-11-05

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What changed

Lonza announced three planned multiproduct bioconjugation suites in Visp, with operations expected from 2028, alongside 500-liter single-use upgrades scheduled for 2027. A November 2 update revised the new facility's maximum scale from 1,200 to 3,000 liters. The capacity remains under development; the announcement does not establish available current commercial slots.

Why it may matter

Analysis: Planned scale flexibility may support ADC programs from development to commercialization; supply planning must account for construction and qualification milestones.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Formulation Development & Manufacturing

Follow the evidence

Related updates

Nature Communications

Peptide–oligonucleotide nanohybrids deliver miRNA to injured bone in rats

A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.

U.S. Food and Drug Administration

FDA grants accelerated approval for subcutaneous amivantamab combination in selected head and neck cancers

FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and an anti-PD-(L)1 antibody. HPV-associated oropharyngeal cancer is excluded. In the 102-patient OrigAMI-4 efficacy population, response rate was 42%. Continued approval requires confirmatory clinical benefit; this is not traditional full approval.

Phillips Medisize / Business Wire

Phillips Medisize acquires full Chippenham site footprint for inhalation development

Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗